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Figure 2. Survival by Retrospective High Resolution HLA Match.
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>¼5/8, <6/8 vs >¼6/8 allelic matches) showed signiﬁcant
reduction in mortality from any cause and non-relapse/
non-disease progression mortality in transplants matched at
>¼6/8 versus <6/8 alleles (p ¼ 0.02 and 0.01, respectively).
Although decreased in incidence, there was no signiﬁcant
association for graft failure, GVHD or infections. In subgroup
comparison using original HLA typing (<3/6 vs >¼3/6, <4/6
vs>¼4/6,<5/6 vs>¼5/6 matches), a signiﬁcant reduction in
mortality from any cause and non-relapse/non-disease
progression mortality was seen in those matched at >¼5/6
versus <5/6 loci (p¼0.05 and 0.01, respectively). Screening
for class I and II AHA was available in 27 patients and was
positive in 8/14 patients with primary graft failure and 3/13
who engrafted. Results were not available for 30/43
engrafters and 5/19 non-engrafters.
Conclusion: HR typing showed an increase in HLA recipient
cord disparity in comparison to standard typing. We
validated the current standard for UCB selection as >¼5/6
grafts were associated with signiﬁcantly improved overall
survival (see Figure 1), which was shown in our >¼6/8 HR
matches as well (see Figure 2). The role of AHA in graft
failure needs to be further tested. In choosing donors for
UCBT, we recommend choosing >¼6/8 HR match especially
when >¼5/6 UCB grafts are available and if able, taking
into account AHA.51
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Out of an estimated 20,000 patients requiring an alloge-
neic HCT in India, only 500 odd patients receive one. Keeping
in cognizance the resource constraints, the major reason for
the discordance lies in the lack of alternate donors. Whilst
unrelated donor marrow and cord sufﬁce for the ethnicmajorities in Europe and the USA, such registries provide for
less than 10% of HCT recipients due to both cost and an
available match. With this background, we initiated a
Haploidentical Family Donor HCT program in 2011.
In our initial screening of 50 patients referred for an
allogeneic BMT, a matched family donor was available in 11
patients and a suitable Haploidentical family donor was
available for 49, whereas a fully matched unrelated donor
(10/10) was available for none. Hence we decided to develop
a Haploidentical BMT program within the available
resources. We chose a Posttransplant Cyclophosphamide
(PTCY) based approach with PBSC as the graft source.
We have carried out 40 transplants in 32 patients over the
last 3 years (AML-15; ALL-2; CML-BC-2; Lymphoma-2;
Severe Aplastic Anemia (SAA)-10; Thalassemia-1). All
received PBSC with PTCY on days 3 and 4 followed by
cyclosporine and MMF. The conditioning regimen comprised
of Fludarabine 150 mg/CY-30 mg/Melphalan-100 mg (SAA)
or 120-140 mg (others) with Fludarabine and IV Busulfan
(6.4-9.6 mg/kg) or Treosulfan 10-12 gm/m2. 2GY TBI was
offered to 4 patients instead of Melphalan. Sirolimus
was added later on day -7 pretransplant to the last 5 patients
with SAA.
30/32 patients surviving beyond 21 days had successful
engraftment with full donor chimerism, including 10/11 pa-
tients with SAA and Thalassemia. 6/8 evaluable patients un-
dergoing a second Haploidentical HCT engrafted as well.
Acute GVHD grade 2-4 developed in 3/32 patients. Day 100
NRM was 5/32 (15%) and the overall survival at 2 years
was 55%. The major cause of NRM was infection with
Carbapenem-resistant Gram Negative Bacilli accounting for
90% of the deaths. Chronic GVHD occurred in 10% of the
evaluable patients. With stringent monitoring for CMV and
preemptive therapy, only 1 patient succumbed to CMV
disease. The outcome and cost of this extremely high risk
group of patients were comparable to matched family donor
BMT. PBSC as graft sourcewas associatedwith a low incidence
of both acute and chronic GVHD.We also studied the effect of
Natural Killer Cell Ligand Mismatch (NKLMM) donor on the
outcome in all our patients. NKLMM was associated with
reduced incidence of relapse in patients with hematological
malignancies (p¼0.03). However, NKLMM donor was asso-
ciated with poor outcome in patients with SAA (p¼0.05).
In summary, Haploidentical HCT based on PTCY and PBSC
graft is feasible and probably the most viable form of
alternate donor HCT in resource constrained settings with
outcomes comparable to matched donor HCT.52
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Background: Mismatched unrelated donor (MMURD)
transplantation is widely used in patients who lack a
matched unrelated donor (MUD). Despite several published
observational studies, the magnitude of risk associated with
9 out of 10 MMURD transplant and that of HLA-speciﬁc
mismatches is still unclear. We performed a meta-analysis to
Table
Clinical outcomes of 9/10 MMURD versus 10/10 MUD by HLA-speciﬁc allele.
Pooled RR (95% CI) Grade II-IV
Acute GVHD
Grade III-IV
Acute GVHD
Chronic
GVHD
Disease-Free
Survival
Overall
Survival
HLA-A 1.12 (0.75-1.66) 1.57 (1.29-1.90) 0.99 (0.68-1.45) 1.20 (1.00-1.45) 1.47 (1.31-1.65)
HLA-B 1.41 (0.63-3.12) 1.67 (1.37-2.03) 0.87 (0.56-1.36) 1.20 (1.04-1.38) 1.33 (1.18-1.51)
HLA-C 1.16 (1.04-1.28) 1.44 (1.25-1.65) 1.04 (0.94-1.16) 1.01 (0.73-1.38) 1.28 (1.13-1.46)
HLA-DRB1 1.60 (1.23-2.09) 1.39 (1.13-1.72) 1.11 (0.68-1.83) 1.16 (0.94-1.44) 1.36 (1.22-1.51)
HLA-DQB1 0.89 (0.37-2.14) insufﬁcient data insufﬁcient data 0.99 (0.71-1.37) 0.95 (0.69-1.31)
HLA-DPB1 2.68 (1.16-6.19) 1.20 (0.94-1.52) 1.06 (0.76-1.46) 0.85 (0.75-0.97) 0.98 (0.89-1.07)
Table
Patient characteristics.
Characteristic MRDnegn[60 MRDposn[20 p-value
Median age in years (range) 33 (1.3-64) 33(10-65) 0.90
Gender, n (%)
Female 28(47) 10 (50) 0.95
Male 32(53) 10 (50)
Race, n (%)
Caucasian 19(42) 26 (58) 0.14
Other 26(58) 19(42)
CMV seropositive , n (%) 44 (73) 13(65) 0.63
Transplant type, n (%)
Flu-Cy-l320 CGV TBI 37(62) 13(65) 1.00
Treo-Flu-200 cGY TBI 23(38) 7(35)
GVHD prophylaxis, n(%)
CSA + MMF 60(100) 20 (100) l.00
CR status, n (%)
1 40(65) 10 (5O) 0.31
2 20(35) 10 (50)
Disease risk
Low/intermediate 33 (55) 7(35) 0.11
High/very high 27(45) 13(65)
Abbreviations: MRD ¼ minimal residual disease, Flu ¼ Fludarabine,
Cy¼Cyclophosphamide, TBI¼ Total body irradiation,GVHD¼ graft versushost
disease, CSA ¼ cyclosporine, MMF¼ mycophenolate mofetil, CR ¼ complete
remission. 1. Signiﬁcance of minimal residual disease before myeloablative
allogeneic hematopoietic cell Transplantation for AML in ﬁrst and second
complete remission. Walter RB et al. Blood 2013;122(10):1813-21.
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MMURD transplant.
Methods: A comprehensive search of Medline and
EMBASE was performed through April 2014. We included
published manuscripts that reported outcomes of adult
patients with hematologic malignancies who underwent
MUD (matched at HLA-A, B, C and DRB1 at a minimum) or
MMURD transplant (single antigen or allele mismatch only).
The pooled relative risks (RR) from hazard ratios and risk
ratios and 95% conﬁdence intervals (CI) were estimated using
a DerSimonian-Laird random-effects model. Heterogeneity
was tested using the I2 statistic and Cochran Q test, and
sources of heterogeneity were evaluated using univariate
meta-regression. Statistical analyses were performed using
Stata v13.1.
Results: Twenty-two studies were included, representing
38,877 transplants. Nine out of 10 MMURD transplant was
associated with a higher risk of overall mortality compared
with 10 out of 10 MUD transplant (n¼10; RR 1.32, 95% CI
1.17e1.49). No signiﬁcant sources of heterogeneity were
identiﬁed. MMURD transplant was associated with worse
disease-free survival compared with MUD transplant (n¼6;
RR 1.20, 95% CI, 1.08e1.33). The pooled effect estimates for
grade II-IV acute and chronic GVHD were 1.23 (n¼4; 95% CI
0.99e1.53) and 1.08 (n¼3; 95% CI 0.76e1.54) respectively.
Single antigen/allele mismatches at HLA-A, B, C or DRB1
were associated with a higher risk of grade III-IV acute GVHD
and overall mortality, but not chronic GVHD as compared
with MUD transplant (Table). Disease-free survival was only
worse for HLA-B mismatch.
Conclusion: MMURD transplant is associated with
signiﬁcantly higher risk of overall mortality and acute GVHD,
but not chronic GVHD compared with MUD transplant. This
risk is associated with HLA-A, -B, -C, and eDRB1, but not
-DQB1 and -DPB1 mismatches.
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Background: Pre-transplant minimal residual disease
(MRD) is associated with inferior outcomes in patients with
acute myeloid leukemia (AML) undergoing myeloablative
hematopoietic cell transplantation (HCT) from related
and unrelated donors1. However data on the impact of
pre-transplant MRD after cord blood transplantation (CBT)
are limited. Using prospectively collected data, we reviewed
80 consecutive patients with AML who received a
myeloablative CBT between 2006 and 2013.
Methods: The myeloablative preparative regimen consisted
of TBI (1320 cGy), Cytoxan and Fludarabine (FLU) (n¼50;62%) or Treosulfan (Treo), FLU and 200 cGY TBI (n¼30; 38%).
Graft-versus-host-disease prophylaxis consisted of cyclo-
sporine and mycophenolate mofetil. Ten-color multiparam-
eter ﬂow cytometry studies on bone marrow aspirates were
performed before HCT to determine the presence of MRD.
Any level of residual disease was considered MRD-positive
(MRDpos).
Results: Pre-transplant MRD was identiﬁed in 20 (25%)
patients. The majority of patients (n¼67; 84%) received a
double-CB graft; the rest received a single-CB graft.
Pre-transplant demographic and clinical characteristics were
similar between the 2 groups (Table). Disease free survival
(DFS) at 5 years was 69% (95% CI: 55-79) and 52% (95% CI:
29-72) for MRDneg and MRDpos patients, respectively
(p¼0.08) (Figure 1A). Figure 1B and 1C show DFS by MRD
for patients receiving different conditioning regimen. After
adjusting for age, disease risk (low/intermediate vs. high/
very high), and CR status (CR1 vs. CR2), the relative
hazard of overall mortality (OM) in the MRDpos group
compared to the MRDneg group was suggestively different
with a HR¼2.36 (95%CI: 1.02-5.43; p¼0.04). However, the
impact of MRD on OM was only signiﬁcant in patients
receiving a Treo based regimen [(HR¼9.5; 95% CI 1.84-49.5)
p¼0.007] while no difference were seen in patients
receiving high-dose TBI [(HR¼1.28; 95% CI 0.44-3.74)
p¼0.64]. Cumulative incidence of relapse was signiﬁcantly
higher in MRDpos patients, 31% (95%CI: 13-52) vs. 10% (95%
CI: 4-20) in MRDneg (p¼0.01) for the group as a whole. An
higher proportion of relapses were observed in MRDpos
